Xiaoxing Cui

Xiaoxing Cui is an experienced professional in corporate development and clinical strategy, currently serving as the Associate Director of Corporate Development at Merck since January 2024. Prior to this role, Xiaoxing held significant positions at Adagene, including Director of Clinical and Corporate Development and Director of Strategy and Corporate Development from January 2021 to January 2023. Xiaoxing's career also includes a role as Director of Business Development and Chief of Staff at Heat Biologics (now Scorpius Holdings) from January 2018 to January 2021, and earlier, as a Primary Researcher and Project Lead at Duke University, where involvement spanned from January 2013 to January 2018. Educational qualifications include a Doctor of Philosophy (PhD) in Integrated Toxicology and Environmental Health from Duke University and a Master of Science in Public Health from The Johns Hopkins University.